Context:
- South Korea’s REGEN Biotech makes AestheFill, a rival to VAIM’s JUVELOOK biostimulator. China’s Imeik controls REGEN (Imeik’s August 21, 2026 interim report), while Bloomage Biotech distributes JUVELOOK in mainland China (Bloomage’s August 28, 2026 interim report, p. 35). In 2017, two years before JUVELOOK launched, REGEN challenged two VAIM patents in Korea and asked the Korean patent tribunal, in a third proceeding, to determine whether VAIM’s process fell within the scope of REGEN’s own patent. All three patents named Kim Geun-poong, the former REGEN vice president who founded VAIM.
- In March 2025, Chinese aesthetics giant IMEIK acquired an 85% controlling stake in REGEN Biotech. Goldman Sachs was appointed to explore a sale.
To Read The Full Story
Continue reading your article with a Membership
